ArticleEpilepsy research2026
A model of new-onset refractory status epilepticus (NORSE) using intrahippocampal kainic acid in adolescent mice.
Article in Epilepsy research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
New-onset refractory status epilepticus (NORSE) is a devastating neurological condition characterized by the sudden onset of prolonged, drug-resistant seizures in previously healthy individuals. A clinically relevant animal model is essential to elucidate its pathophysiology, improve treatment, and reduce morbidity and mortality in NORSE. We developed an adolescent mouse model of NORSE by inducing prolonged convulsive status epilepticus in postnatal day 40 (P40) C57BL/6 J mice-corresponding to human adolescence-via unilateral intrahippocampal kainic acid (IHKA, 150 ng) injection. Progression of recurrent spontaneous electrographic seizures was monitored through depth electrodes on days 3, 5, 7, and 21 post-IHKA. Cellular and immune responses were examined using immunohistochemistry, Nissl staining, and flow cytometry. Behavioral outcomes were assessed using open-field and Y-maze tests. IHKA-injected mice developed spontaneous recurrent seizures by day 3 (18.7 ± 3.2 seizures/hour). Seizure frequency nearly doubled by day 7 (35.2 ± 4.1 seizures/hour) and continued through day 21 (39.7 ± 4.8 seizures/hour). Significant neuroinflammatory changes were observed, including > 9-fold microglia activation, two-fold astrocytosis, cell death in the CA3 subfields, and monocyte infiltration into the hilus. Flow cytometry revealed a two-fold increase in CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.